Ingalls & Snyder LLC Has $1.61 Million Position in Codexis, Inc. (NASDAQ:CDXS)

Share on StockTwits

Ingalls & Snyder LLC lessened its position in Codexis, Inc. (NASDAQ:CDXS) by 3.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 100,432 shares of the biotechnology company’s stock after selling 4,100 shares during the period. Ingalls & Snyder LLC’s holdings in Codexis were worth $1,606,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Gilder Gagnon Howe & Co. LLC increased its holdings in Codexis by 9.6% in the 3rd quarter. Gilder Gagnon Howe & Co. LLC now owns 2,749,699 shares of the biotechnology company’s stock worth $37,712,000 after purchasing an additional 241,799 shares in the last quarter. Vanguard Group Inc. increased its holdings in Codexis by 7.7% in the 2nd quarter. Vanguard Group Inc. now owns 2,592,842 shares of the biotechnology company’s stock worth $47,786,000 after purchasing an additional 184,476 shares in the last quarter. Nikko Asset Management Americas Inc. increased its holdings in Codexis by 79.1% in the 3rd quarter. Nikko Asset Management Americas Inc. now owns 1,402,457 shares of the biotechnology company’s stock worth $19,235,000 after purchasing an additional 619,524 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its stake in shares of Codexis by 79.1% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,402,457 shares of the biotechnology company’s stock valued at $19,235,000 after buying an additional 619,524 shares during the period. Finally, First Light Asset Management LLC increased its stake in shares of Codexis by 66.6% in the second quarter. First Light Asset Management LLC now owns 1,205,523 shares of the biotechnology company’s stock valued at $22,218,000 after buying an additional 481,763 shares during the period. 89.40% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts have recently weighed in on CDXS shares. BidaskClub raised Codexis from a “hold” rating to a “buy” rating in a research note on Wednesday. HC Wainwright reissued a “buy” rating and issued a $22.50 price target on shares of Codexis in a research note on Tuesday, December 24th. ValuEngine cut Codexis from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 4th. Finally, Zacks Investment Research cut Codexis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 14th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Codexis currently has a consensus rating of “Buy” and an average price target of $20.63.

NASDAQ CDXS opened at $18.50 on Thursday. The business has a 50 day simple moving average of $16.43 and a 200 day simple moving average of $15.50. Codexis, Inc. has a one year low of $12.68 and a one year high of $22.49. The stock has a market capitalization of $1.09 billion and a P/E ratio of -88.10. The company has a debt-to-equity ratio of 0.25, a current ratio of 7.37 and a quick ratio of 7.34.

Codexis (NASDAQ:CDXS) last released its earnings results on Tuesday, November 5th. The biotechnology company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.09) by $0.10. Codexis had a negative return on equity of 15.24% and a negative net margin of 17.85%. The business had revenue of $21.91 million during the quarter, compared to analysts’ expectations of $16.56 million. Equities analysts expect that Codexis, Inc. will post -0.2 earnings per share for the current year.

In other Codexis news, Director Thomas R. Baruch sold 17,500 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $15.61, for a total value of $273,175.00. Following the transaction, the director now owns 90,540 shares in the company, valued at $1,413,329.40. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Dennis P. Wolf sold 20,000 shares of the stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $16.22, for a total value of $324,400.00. Following the completion of the transaction, the director now owns 102,177 shares in the company, valued at approximately $1,657,310.94. The disclosure for this sale can be found here. Company insiders own 10.70% of the company’s stock.

Codexis Profile

Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.

Read More: Guidelines for Successful Channel Trading

Want to see what other hedge funds are holding CDXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Codexis, Inc. (NASDAQ:CDXS).

Institutional Ownership by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Nisa Investment Advisors LLC Purchases 500 Shares of Wingstop Inc
Nisa Investment Advisors LLC Purchases 500 Shares of Wingstop Inc
Nisa Investment Advisors LLC Acquires 5,038 Shares of Community Healthcare Trust Inc
Nisa Investment Advisors LLC Acquires 5,038 Shares of Community Healthcare Trust Inc
Louisiana State Employees Retirement System Has $294,000 Position in Chatham Lodging Trust
Louisiana State Employees Retirement System Has $294,000 Position in Chatham Lodging Trust
Nisa Investment Advisors LLC Purchases 100 Shares of Silicon Laboratories
Nisa Investment Advisors LLC Purchases 100 Shares of Silicon Laboratories
Spotify  Shares Purchased by Nisa Investment Advisors LLC
Spotify Shares Purchased by Nisa Investment Advisors LLC
BGC Partners, Inc.  Shares Acquired by Nisa Investment Advisors LLC
BGC Partners, Inc. Shares Acquired by Nisa Investment Advisors LLC


 
© 2006-2020 Zolmax.